A multicenter, randomized control study to assess the safety and efficacy of IVIG plus clarithromycin, a biofilm modulator for Kawasaki disease. - A multicenter, randomized control study to assess the safety and efficacy of IVIG plus clarithromycin, a biofilm modulator for Kawasaki disease (KPISG-KYUKID)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University0 个研究点目标入组 90 人开始时间: 2014年10月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients planning to receive systemic steroid therapy in the initial therapy. 2. Patients with past histories of hypersensitivity reaction against clarithromycin or other macrolide drugs. 3. Patients currently receiving medications that are known to interact with clarithromycin (digoxin, carbamazepine, theophylline, aminophylline, cyclosporine, tacrolimus, benzodiazepine, disopyramide, nifedipine, verapamil, sildenafil citrate, warfarin, rifampin etc.) 4. Patients diagnosed on the ninth day of illness or later (the first illness day is defined as the day when the patient develops a fever). 5. Patients with coronary lesions before starting treatment. 6. Patients with past histories of Kawasaki disease (recurrent cases). 7. Patients with serious active bacterial infection as sepsis. 8. Patients having received IVIG within 90 days. 9. Patients with severe underlying disease (immunodeficiency, chromosomal anomalies, congenital heart diseases, metabolic diseases, collagen diseases, etc.

发起方

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University